Realized value of platform-based biotech: a retrospective analysis of 220 companies
- By Maggie Pickard, Allison Cremer, and Jason Brauner
- Biopharma
We explore four hypothesized value drivers of platform-based companies and evaluate the actual value achieved 10-15 years out from initial capital raise. We found that discovery platforms showed the highest lead asset success rates, significantly more out-licensing activity than non-platforms, and accounted for nearly all multi-asset approvals within our cohort. All platform types showed increased survivability and more licensing opportunities.